Retina care specialists

Palm Beach Gardens, Florida 45674

2 studies enrolling now · 20 studies all time

What they study most

Age Related Macular Degeneration, Age-Related Macular Degeneration, Age-related Macular Degeneration (AMD), Choroidal Neovascularization, Diabetic Macular Edema, Geographic Atrophy, Geographic Atrophy (GA), Macular Degeneration, Neovascular Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Age Related Macular Degeneration, Wet Macular Degeneration

Studies at this site

• A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy — Recruiting now
• Extension Study for the Port Delivery System With Ranibizumab (Portal) — Recruiting now
• A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy — Recruiting now
• A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 — Running, not enrolling
• Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy — Completed
• A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1) — Completed
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema — Completed
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration — Completed
• A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE) — Completed
• A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) — Completed
• A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration — Completed
• A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) — Completed
• A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration — Completed
• A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy — Completed
• An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy — Stopped early
• A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Stopped early
• Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) — Stopped early
• Sensitivity of the Home Macular Perimeter (HMP) — Completed
• A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration — Completed